Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study in Subjects With Retinitis Pigmentosa
Sponsor: Aldeyra Therapeutics, Inc.
Summary
An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.
Official title: An Open-label, Phase II Study of ADX-2191 in Subjects With Retinitis Pigmentosa
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
8
Start Date
2022-07-14
Completion Date
2023-06-23
Last Updated
2026-04-23
Healthy Volunteers
No
Conditions
Interventions
ADX-2191
Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16.
ADX-2191
Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16.
Locations (1)
Duke Eye Center
Durham, North Carolina, United States